DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Read / Leggi Disclaimer

Spectral AI ( $MDAI ): DeepView, BARDA backing, FDA De Novo path,

Spectral AI is one of those very small companies where the story looks simple on the surface and much more complicated once you open the hood. The company is trying to bring its DeepView burn-imaging platform through the FDA while using non-dilutive government support to fund part of the journey. The setup is interesting because it combines a real clinical problem, a potentially differentiated imaging workflow, and a government countermeasure angle. The catch is that this is still a micro-cap name with execution risk, regulatory risk, and financing risk that cannot be ignored.

ProKidney (PROK) after FY 2025 earnings

ProKidney’s FY 2025 release did not deliver a dramatic twist, and that is exactly why it matters. Investors were not looking for revenue, because there is none. They were not looking for normal operating leverage, because this is still a pre-commercial biotech. What they needed to see was whether the company could still credibly defend the bridge from today’s balance sheet to the one milestone that truly matters, the Q2 2027 Phase 3 eGFR-slope readout in PROACT 1. For now, the answer remains yes.

SeaStar Medical ( $ICU ) before FY2025 earnings

SeaStar Medical goes into its March 25, 2026 earnings date with a story that is more credible medically than it was a few months ago, but not yet more comfortable financially. That distinction matters. In ultra-small medtech and biotech names, better clinical framing can improve perception, but it does not automatically repair a pressured capital structure. SeaStar’s recent updates created a more solid pediatric narrative around QUELIMMUNE, yet the company still faces the far more difficult question of whether that narrative can become durable adoption, durable funding and a less fragile 2026 outlook.

Protalix BioTherapeutics (PLX) reported fiscal 2025 results on March 18 2026

Protalix BioTherapeutics (PLX) reported fiscal 2025 results on March 18, 2026, with $51.8 million in revenues from selling goods, $52.7 million in total revenues, and a net loss of $6.6 million. The most important near-term development was not just the annual print itself, but the combination of that print with the European Commission approval of the every-four-weeks dosing regimen for Elfabrio, which triggered a $25 million milestone payment from Chiesi.

Aldeyra ( $ALDX ) : 3 attempts were not enough

I deliberately waited at least one full day before writing this piece. Not to stall, but to look at the March 17, 2026 Complete Response Letter with a colder head, outside the immediate chaos of the tape. What follows is not a quick reaction article. It is a long-form reconstruction of how Aldeyra reached a third rejection in dry eye disease, why that matters far beyond one bad headline, where management deserves a tougher standard, and whether any credible path still exists for reproxalap in DED.

Kosmos Energy Ltd ( $KOS ) Deep Dive Update

Kosmos Energy is one of those companies that can look dramatically different depending on the lens used. If the lens is geology and resource base, there is real substance here: Ghana remains a meaningful production engine, GTA has moved from long-promised concept into actual LNG production, and the company still retains additional development and exploration optionality. If the lens is capital structure, however, the picture is much less forgiving. High debt, prior operational disappointments, start-up cost inflation, and the need to actively manage maturities have made KOS a much harder story for equity investors than a simple “oil up, stock up” thesis.

Ovid Therapeutics Inc ( $OVID ) expanded deep dive on OV329, the KCC2 platform, capital structure, dilution risk, and the 2026 catalyst path

Ovid Therapeutics is a New York-based biopharmaceutical company focused on small-molecule medicines for brain disorders driven by impaired inhibitory signaling and neuronal hyperexcitability. The current story is built around two mechanistic pillars: OV329, a next-generation GABA-AT inhibitor for refractory epilepsies, and OV4071, a first-in-class oral KCC2 direct activator for psychosis-related and broader neuropsychiatric indications.

What makes Ovid more interesting now than a few quarters ago is not just pipeline breadth, but the combination of fresh clinical support, a much stronger balance sheet, and a clearer 18–24 month cadence of milestones. On March 18, 2026, the company reported new 7 mg OV329 safety and PK data, expanded OV329 into tuberous sclerosis complex seizures and infantile spasms, confirmed Australian clearance for OV4071 Phase 1 work, and paired those updates with a new $60.0 million private placement. That package materially changed the near-term risk profile versus the leaner cash position seen in 2025.

Artelo Biosciences ( $ARTL ) — Full Deep Dive March 2026

Artelo is one of those names where two truths live side by side and both matter. The first truth is that this is not an empty shell. The pipeline is real, there are multiple shots on goal, and at least two of the programs have enough substance to justify serious attention from specialist biotech traders. ART27.13 has generated actual human data in cancer-related anorexia and now has a new ophthalmology expansion angle in glaucoma or ocular hypertension. ART26.12 has crossed the line into human testing with a completed single-ascending-dose study. ART12.11, while earlier, has regulatory progress and intellectual-property support that make it more than just a speculative line item.

Palladyne AI  ( $PDYN ) Defense stack now forming

Executive view. Today’s Navy ALRRM award matters, but not because the dollar amount alone changes the company overnight. What matters is that the award fits into a sequence that has become hard to ignore: first the AFRL HANGTIME work, then the missile propulsion subsystem contract, then the post-acquisition repositioning around GuideTech and defense manufacturing, and now a Navy near-hypersonic missile development award. Put differently, PDYN is no longer just trying to sell an autonomy story. It is trying to become a more complete defense-and-industrial platform where software, avionics, manufacturing, propulsion and program access all reinforce each other.

ZenaTech ( $ ZENA) adds a new low-cost interceptor drone to the counter-UAS story

Quick take. This is a meaningful story update, not a fundamental de-risking event. ZenaTech says it is developing a low-cost, single-use autonomous interceptor drone called Interceptor P-1 for the broader ZenaDrone counter-UAS platform. The logic is clear: defeat cheap hostile drones with cheaper, faster, more scalable interceptors instead of relying only on high-cost conventional air-defense responses. That makes conceptual sense. What still matters more, however, is the gap between concept and proof: this remains a development-stage defense product announcement, not a disclosed contract, not a production milestone, and not a booked revenue line.

Ondas Inc Evolution 2026( $ONDS )

EN IT Ondas, Evolution How ONDS is trying to become a multi-domain defense platform in 2026 — and why the story now looks both more coherent and more demanding than it did just a few months ago. Ticker: ONDS Focus:…

Greenwich LifeSciences ( $GLSI ): FLAMINGO-01 Reorders the Story, but the Trial Is Still Binary

GLSI is exactly the kind of name that can look much cleaner in a press release than it does in real portfolio construction. The company has one lead asset, one pivotal clinical thesis, limited cash, ongoing need for financing, and a story that can produce violent stock reactions because the float is relatively small and the clinical promise is easy to narrate. That is why the most useful way to rebuild the article in the new format is to put the scientific signal and the financing reality in the same frame from the first page.

Planet Labs PBC ( $PL )

Planet Labs—not NVIDIA—officially announced on March 16, 2026 that it is building a GPU-native AI engine for planetary intelligence with NVIDIA. The news matters not because it creates a completely new Planet story, but because it reinforces a strategic transition Merlintrader had already identified: Planet is moving beyond raw imagery delivery toward a faster, higher-value geospatial intelligence layer built on AI processing, semantic search and real-time operational utility.
By Merlintrader | Updated March 17, 2026

Olema Pharmaceuticals Inc ( $OLMA )  deep dive march 17 2026

Olema sits in one of the most interesting transition zones in clinical-stage biotech. It is no longer a company that can be dismissed as little more than a speculative preclinical story, because it now has a late-stage development strategy centered on palazestrant, a second clinical engine in OP-3136, and a balance sheet that looks strong enough to bridge the company through several major milestones. At the same time, Olema is not yet a diversified oncology company with multiple independent late-stage assets that can absorb a major failure without a violent valuation reset. That is why the stock remains so fascinating. It offers a genuine setup for a re-rating if execution continues, but it also remains highly exposed to a narrow band of high-information events.

Momentus Inc ( $MNTS )– complete deep dive on the recent timeline, government milestones, customer contracts, backlog signals, cash stress and execution risk

Momentus is one of those small-cap space names that keeps surviving by refusing to stay simple. If you look only at the financial statements, MNTS still looks fragile: revenue is very small, cash remains thin, net losses are large relative to the company’s size, and the latest quarterly filing still explicitly raised substantial doubt about the company’s ability to continue as a going concern. But if you look only at the press releases, you get a different picture: government-linked milestones, NASA work, DARPA-related progress, U.S. Space Force vehicle eligibility, commercial payload partnerships, and a near-term mission that could function as an operational showcase.

Structure Therapeutics Inc ADR ( $GPCR ) DD march 16 2026

Structure Therapeutics was founded with a singular mission: to build a structure-based GPCR (G-protein-coupled receptor) drug discovery platform. The company's name literally reflects its core intellectual property—the belief that understanding the three-dimensional structure of GPCR proteins could enable design of highly selective, potent small molecule drugs that traditional high-throughput screening couldn't easily find.

Annovis Bio ( $ANVS ) – Deep Dive on Buntanetap 2026

Annovis is one of those biotech names that looks tiny on the screen but can become very large in narrative terms whenever the market wants a fresh Alzheimer’s angle. The company’s March 16, 2026 fiscal-year update did not announce an approval, an acquisition or a phase-changing headline readout. What it did provide was something more practical: a clean status check on the one thing that matters most for Annovis today, namely whether its pivotal Alzheimer’s program is moving forward fast enough to keep the investment story alive before the cash window narrows too much.

United States Antimony ( $UAMY ) – Pentagon Demand, Commercial Scale and the 2026 Execution Test

United States Antimony Corporation (NYSE American: UAMY) has positioned itself as a critical-minerals player through two landmark contracts announced in late 2025: a five-year, sole-source IDIQ agreement with the U.S. Defense Logistics Agency worth up to $245 million, and a new five-year commercial supply deal with a major U.S. industrial fabric manufacturer valued at approximately $107 million. Together, these contracts—announced over a 60-day period in September–October 2025—represent combined long-term visibility of up to $352 million.

NRx Pharmaceuticals ( $NRXP ) – FDA Minutes Lock In the NRX-100 NDA Path

NRx Pharmaceuticals finally got the kind of news biotech traders usually wait for: not just another optimistic corporate interpretation, but formal written FDA minutes that document the regulatory path. In today’s release, the company said it received the confirmatory written minutes from its February 17, 2026 in-person Type C meeting with the FDA. According to NRx, those minutes support a path to file an NDA for NRX-100 by June 2026 using existing adequate and well-controlled clinical trial data together with confirmatory Real World Evidence. The company also said the FDA confirmed that no additional clinical trials and no bridging studies are required for the preservative-free formulation